Lille, France; Cambridge, MA; April 22, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced that Thomas Baetz has been appointed as Chief Financial Officer. Thomas Baetz joins the Executive Committee, along with Stefanie Magner, Chief Compliance Officer.

GENFIT hires Thomas Baetz as Chief Financial Officer and adds two new members to its Executive Committee

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *